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Abstract: According to the World Health Organization, traumatic injuries worldwide are responsible for
over 5 million deaths annually. Post-traumatic bleeding caused by traumatic injury-associated coagu-
lopathy is the leading cause of potentially preventable death among trauma patients. Despite these facts,
awareness of this problem is insufficient and treatment options are often unclear. The STOP the Bleed-
ing Campaign therefore aims to increase awareness of the phenomenon of post-traumatic coagulopathy
and its appropriate management by publishing European guidelines for the management of the bleeding
trauma patient, by promoting and monitoring the implementation of these guidelines and by preparing
promotional and educational material, organising activities and developing health quality management
tools. The campaign aims to reduce the number of patients who die within 24 hours after arrival in the
hospital due to exsanguination by a minimum of 20% within the next 5 years.
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Introduction
Injuries worldwide cause more than 16,000 deaths per 
day [1]. Bleeding is a leading cause of death following 
traumatic injury for those patients who are admitted to 
hospital, and trauma-associated coagulopathy increases 
both the risk and severity of bleeding. At least 20% of 
severely injured patients (Injury Severity Score ≥16) are 
already coagulopathic upon arrival in the emergency 
room [2-4], but awareness of this problem is low, leading 
to late recognition and delayed trea tment of coagulo-
pathy. Th is lack of awareness may cause harm to our 
patients, because the coagulopathy associated with 
traumatic injury contributes signiﬁ cantly to secondary 
injury and results in a several-fold increase in morbidity 
and mortality [5,6]. Moreover, diagnostic and treatment 
options are often unclear and not well investigated.
Inspired by the success of two other medical awareness 
campaigns – the Anti-Obesity Campaign created in 1999 
[7] and the Surviving Sepsis Campaign launched in 2002 
[8] – a multidisciplinary, pan-European group of experts 
with specialties in surgery, anaesthesia, emergency 
medicine, intensive care medicine and haematology are 
now in the process of launching a campaign to counteract 
preventable deaths from uncontrolled bleeding following 
traumatic injury. Th is task force, including represen ta-
tives of relevant European professional societies  – the 
European Society of Anaesthesiology, the European 
Society of Intensive Care Medicine, the European Shock 
Society, the European Society of Trauma and Emergency 
Surgery and the European Society for Emergency 
Medicine – published a review article [9] and developed 
guidelines for the management of the bleeding trauma 
patient, which have been updated at 3-year intervals [10-
12]. Th e group believes that an active campaign to 
improve awareness of traumatic coagulopathy will help to 
ensure that guideline recommendations are universally 
implemented.
Aim and acronym of the STOP the Bleeding 
Campaign
Th e STOP the Bleeding Campaign aims to reduce 
morbidity and mortality from bleeding following trau-
matic injury by implementing a programme to support 
haemostatic resuscitation that includes clinical practice 
guidelines, patient management bundles, educational 
tools and adherence control measures to ensure the early 
recognition and treatment of bleeding and traumatic 
coagulopathy. Th e goal of the campaign is to reduce the 
number of patients who die within 24 hours after arrival 
in hospital due to exsanguination by a minimum of 20% 
within 5 years.
Th e acronym STOP comprises the following elements: 
Search for patients at risk of coagulopathic bleeding; 
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Treat bleeding and coagulopathy as soon as they develop; 
Observe the response to interventions; Prevent secon-
dary bleeding and coagulopathy.
Search for patients at risk of coagulopathic bleeding
Th e early recognition of bleeding and coagulopathy 
requires awareness of the phenomenon. Although the 
Advanced Trauma Life Support programme addresses 
the circulatory problem during the primary survey and 
suggests that bleeding sources should be sought if shock 
is present [13], the issue of coagulopathy associated with 
traumatic injury is not well addressed at present. Th e 
STOP concept speciﬁ cally addresses three important 
aspects of coagulo pathic bleeding: rapid detection of all 
relevant bleeding sources; estimation of blood loss, risk 
of ongoing haemorrhage and need for massive 
transfusion; and targeted screening for and monitoring of 
coagulopathy upon arrival in hospital and intermittently 
thereafter.
Treat bleeding and coagulopathy as soon as they develop
Bleeding should be stopped using surgical or other means 
as quickly as possible. Damage control surgery should be 
applied to patients in shock, including packing of the 
abdomen in haemorrhagic patients, application of external 
ﬁ xators to long bone fractures and an attempt to limit 
operation times to ≤90 minutes per intervention. Aggres-
sive treatment of coagulopathy should be implemented 
simultaneously, including the early administration of 
tranexamic acid and the use of blood products according 
to evidence-based clinical practice guidelines.
Observe the response to interventions
After treatment, the response to intervention should be 
observed. Important variables to be considered include 
the surgeon’s interoperative judgement, laboratory tests, 
thrombelastometric assessment and the necessity of 
continued blood product administration. Th e vital 
status – especially blood pressure, pulse rate, lactate and 
urinary output – should also be evaluated.
Prevent secondary bleeding and coagulopathy
Especially important is the avoidance of secondary 
coagulopathy. Measures may include the use of damage 
control surgery rather than primary deﬁ nitive surgery in 
patients in shock and the prevention of all risk factors 
that trigger haemostatic disorders, including hypo-
thermia and acidosis.
Main action points for implementation
To achieve these goals, several important action points 
must be undertaken in parallel. Th e campaign must be 
visible not only for researchers but also for clinicians 
involved in the treatment of bleeding trauma patients. 
Although published national and international guidelines 
that reﬂ ect the current evidence and a scientiﬁ c 
evaluation of state-of-the-art diagnostic and treatment 
options and that identify areas which require further 
research are helpful to guide the clinician in the 
treatment of the bleeding trauma patient, the translation 
into clinical practice represents a challenge for busy 
clinicians, particularly in an emergency setting. Th e 
campaign therefore aims to develop and test diagnostic 
and interventional patient management bundles to aid in 
the learning and implementation process, as demon-
strated during the Surviving Sepsis Campaign [14].
Evidence from the Surviving Sepsis Campaign has also 
shown that the adherence to the management bundles 
must be monitored and  – more importantly  – is asso-
ciated with an increase in survival [15]. We therefore aim 
to create a technical tool that can be used to monitor and 
document institutional adherence to patient management 
principles in national or international databases. If 
possible, these databases should be aligned to permit 
comparative eﬀ ectiveness research.
In addition, awareness and implementation of the 
principles represented by the STOP the Bleeding 
Campaign should be supported by educational pro-
grammes, and adaptation of the guiding principles to the 
local situation in each institution and the eﬀ ectiveness of 
the programme should be evaluated using validated tools 
on a periodic basis.
Support and funding
Th e experts initiating the STOP the Bleeding Campaign 
request the support of European professional societies, 
political bodies, national and international health and 
funding organisations as well as pharmaceutical and 
device manufacturers. If these diverse groups recognise 
and accept the challenge presented by the bleeding 
trauma patient and enable a global campaign to induce 
clinicians involved in the treatment of the trauma patient 
to embrace evidence-based management principles, it 
will be possible to decrease mortality due to 
exsanguination in the coming years.
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